Paratek Pharmaceuticals Announces First Quarter 2020 Total Revenues of $7.9 Million including NUZYRA® (omadacycline) Net Sales of $7.3 Million
Stock Information for Paratek Pharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.